EA201001589A1 - Immobilized erythropoietin - Google Patents

Immobilized erythropoietin

Info

Publication number
EA201001589A1
EA201001589A1 EA201001589A EA201001589A EA201001589A1 EA 201001589 A1 EA201001589 A1 EA 201001589A1 EA 201001589 A EA201001589 A EA 201001589A EA 201001589 A EA201001589 A EA 201001589A EA 201001589 A1 EA201001589 A1 EA 201001589A1
Authority
EA
Eurasian Patent Office
Prior art keywords
erythropoietin
treatment
encapsulated
immobilized
polymer
Prior art date
Application number
EA201001589A
Other languages
Russian (ru)
Other versions
EA018472B1 (en
Inventor
Вадим Юрьевич Балабаньян
Хафез Ахмед Яссир Хамди Махмуд Абдель
Игорь Николаевич Солев
Таисия Леоновна ГАРИБОВА
Татьяна Александровна ВОРОНИНА
Ольга Сергеевна Шелудченко
Original Assignee
Открытое Акционерное Общество "Протек"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Открытое Акционерное Общество "Протек" filed Critical Открытое Акционерное Общество "Протек"
Priority to EA201001589A priority Critical patent/EA018472B1/en
Publication of EA201001589A1 publication Critical patent/EA201001589A1/en
Publication of EA018472B1 publication Critical patent/EA018472B1/en

Links

Abstract

Предложен эритропоэтин (ЭПО), представляющий собой рекомбинантный человеческий или модифицированный эритропоэтин альфа, или его аналог, инкапсулированный в наночастицы и/или микрочастицы из фармацевтически пригодных, биосовместимых и биодеградируемых (со)полимер(ов) и/или полимерных матриц, и/или сорбированный и/или адсорбированный на их поверхности, и/или инкапсулированный в липосомы. Новая форма эритропоэтина может быть использована для создания лекарственных препаратов для лечения и/или профилактики неврологических и гематологических заболеваний и нарушений, а также для лечения нарушений зрения, ретинопатии при недоношенности и др.Erythropoietin (EPO), which is a recombinant human or modified erythropoietin alpha, or its analog encapsulated in nanoparticles and / or microparticles from pharmaceutically acceptable, biocompatible and biodegradable (co) polymer (s) and / or polymer matrices, and / or sorbated and / or adsorbed on their surface, and / or encapsulated in liposomes. A new form of erythropoietin can be used to create drugs for the treatment and / or prevention of neurological and hematological diseases and disorders, as well as for the treatment of visual impairment, retinopathy with prematurity, etc.

EA201001589A 2010-09-15 2010-09-15 Erythropoietin-containing particles for treatment and prophylaxis of neurologic and hematologic diseases and disorders EA018472B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EA201001589A EA018472B1 (en) 2010-09-15 2010-09-15 Erythropoietin-containing particles for treatment and prophylaxis of neurologic and hematologic diseases and disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EA201001589A EA018472B1 (en) 2010-09-15 2010-09-15 Erythropoietin-containing particles for treatment and prophylaxis of neurologic and hematologic diseases and disorders

Publications (2)

Publication Number Publication Date
EA201001589A1 true EA201001589A1 (en) 2012-02-28
EA018472B1 EA018472B1 (en) 2013-08-30

Family

ID=45908217

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001589A EA018472B1 (en) 2010-09-15 2010-09-15 Erythropoietin-containing particles for treatment and prophylaxis of neurologic and hematologic diseases and disorders

Country Status (1)

Country Link
EA (1) EA018472B1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030035845A1 (en) * 1992-06-11 2003-02-20 Zale Stephen E. Composition for sustained release of non-aggregated erythropoietin
WO1999038536A1 (en) * 1998-01-29 1999-08-05 Poly-Med Inc. Absorbable microparticles
DK0937456T3 (en) * 1998-02-23 2004-11-08 Cilag Ag Int Liposomal dispersion of erythropoietin
RU2271196C2 (en) * 1999-06-04 2006-03-10 Элзэ Копэрейшн Implantable composition (variants) and method for production thereof
US7879361B2 (en) * 2005-01-04 2011-02-01 Gp Medical, Inc. Nanoparticles for drug delivery
CN101507712B (en) * 2009-03-20 2011-08-17 河北师范大学 Sustained-release micro-spheres preparation containing recombined erythropoietin

Also Published As

Publication number Publication date
EA018472B1 (en) 2013-08-30

Similar Documents

Publication Publication Date Title
EP3300728A3 (en) Treatment of circadian rhythm disorders
BR112013003677A2 (en) use of pharmacologically active agent and pharmaceutical dosage form
EA201300669A1 (en) SUBSTITUTED 1-BENZYL CYCLOALKYL CARBONIC ACIDS AND THEIR APPLICATION
PH12015500407A1 (en) Methods of treating hypertriglyceridemia
EP3050876A3 (en) Kinase modulators
UA108198C2 (en) Substituted 2-acetamido-5-aryl-l, 2,4-triazolones and their use
BR112013015859A2 (en) compound, use of a compound, methods of prevention, treatment, amelioration or prophylaxis of physiological disorders or diseases, and treatment or amelioration of cosmetic indications, and, pharmaceutical composition
WO2013184876A8 (en) Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof
WO2009111317A3 (en) Endoscopic delivery of red/nir light to the substantia nigra to treat parkinson's disease
MX2015002289A (en) Human antibodies to gfrî±3 and methods of use thereof.
EP2268140A4 (en) Novel compounds advantageous in the treatment of central nervous system diseases and disorders
IN2014DN06710A (en)
MX2019000547A (en) Stabilized liquid and lyophilized adamts13 formulations.
CL2012001673A1 (en) Substituted benzamide derivative compounds, as modulators of taar; preparation procedure; pharmaceutical composition; and its use in the treatment of depression, anxiety disorders, bipolar disorder, schizophrenia, epilepsy, migraine, Alzheimer's disease, metabolic disorders, among others.
MX2014008842A (en) Dental implant and method for producing a dental implant.
MX2012004078A (en) Compounds and compositions as modulators of gpr119 activity.
GB2496800B (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
BR112012030331A2 (en) neuregulin isoforms, neuregulin polypeptides, and uses thereof
EA201171283A1 (en) NEW TECHNOLOGY OF MELOXICAM MANUFACTURE
EP3300734A3 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
WO2014106116A3 (en) Therapeutic compositions comprising antibodies
BR112014011744A2 (en) sustainable action formulation of cyclosporine form 2
EA201492102A1 (en) ANTAGONISTS LINGO-2 FOR THE TREATMENT OF DISEASES IN WHICH MOTOR NEURONS PARTICIPATE
IN2014KN02687A (en)
EA201690005A1 (en) COMPOSITION WITH MODIFIED EXTRUSION KINETICS

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KZ RU

NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): AZ BY KZ RU

NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): AM KG MD TJ TM

TC4A Change in name of a patent proprietor in a eurasian patent
PC4A Registration of transfer of a eurasian patent by assignment